to evaluate whether serotonin reuptake inhibition is critical to the treatment of obsessive-compulsive disorder , 40 outpatients with a principal diagnosis of obsessive-compulsive disorder were randomized in a double-blind fashion to 8 weeks of treatment with either the serotonin reuptake inhibitor fluvoxamine maleate ( n = 21 ) or the norepinephrine reuptake inhibitor desipramine hydrochloride ( n = 19 ) .
C0028768
obsessive-compulsive disorder
C0700473
fluvoxamine